The Journal of Allergy and Clinical Immunology: In Practice
Review and Feature ArticleSystematic Assessment of Difficult-to-Treat Asthma: Principles and Perspectives
Section snippets
The Need for Systematic Assessment (Table I)
Difficult-to-treat asthma is heterogeneous and complex, involving a multitude of potentially targetable pulmonary, extrapulmonary and behavioral traits.9,10 Most patients with difficult-to-treat asthma have modifiable risk factors for poor asthma control,5 and failure to address them may result in poorer outcomes.11,12 Systematic assessment therefore acts as a cognitive tool to ensure that all essential elements are addressed.13,14 This evaluation process cannot be assumed, as many key aspects
Improved processes
The broad range of deficiencies in care outlined above can be overcome with an assessment system that is comprehensive, holistic, and multidisciplinary.
A comprehensive approach with standardized steps for all patients can prevent the important omissions and reduce the variability with which different specialists have been shown to respond to the same case scenario.43
A holistic approach expands the evaluation beyond an airway-centric approach to encompass additional domains of extrapulmonary
Selecting Patients for Systematic Assessment
Systematic assessment of patients with difficult-to-treat asthma is resource-intensive. It should be prioritized for patients with the greatest complexity and disease burden who, according to responder analysis, derive the most benefit.50 Ideally, it should form the concluding stage of an integrated, coordinated approach to asthma that spans primary and secondary care.56
The prevalence of difficult-to-treat asthma in the community is reportedly as high as 17% of all adult asthma.57 The figure
Service configuration
The model by which systematic assessment is delivered is usually tailored to the overall goal. This goal can range from providing assessment only, to providing the totality of care, inclusive of both assessment and treatment (Figure 1).
An “assessment-predominant” model allows completion of the entire diagnostic process in an intensive 1-day visit, leaving treatment recommendations to be implemented by the referring specialist.48 This model relies on the referrer having subsequent access to
Domains of Systematic Assessment
Systematic assessment of difficult-to-treat asthma focuses on 3 broad domains: asthma itself, comorbidities, and patient factors. Within each domain, specific issues are often found to be recurring and important contributors to difficult-to-treat asthma.
Specific Paediatric Considerations
Systematic assessment of difficult-to-treat asthma is just as beneficial in children as in adults,136 but there are key differences between adult and pediatric practice.137 First, the assessment is centered on the family rather than the patient. Psychosocial morbidity, frequently related to parent/carer influence, is common in children with difficult-to-treat asthma, and exploration of these factors through home and school visits can be revealing.138 The child probably cannot modify factors
Conclusion
Systematic assessment for difficult-to-treat asthma is beneficial and necessary to address the needs of this challenging population. Specific components of the assessment and how these are delivered may vary between health care settings, but there is broad consensus on the main domains of assessment. A substantial range of clinical expertise is required to address patient complexity, and delivering multidisciplinary systematic assessment requires specific resource allocation and training for
References (140)
- et al.
Differentiation of adult severe asthma from difficult-to-treat asthma—outcomes of a systematic assessment protocol
Respir Med
(2018) - et al.
Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol
Chest
(1993) - et al.
After asthma: redefining airways diseases
Lancet
(2018) - et al.
Profile of difficult to treat asthma patients referred for systematic assessment
Respir Med
(2016) - et al.
The level of diagnostic assessment in severe asthma: a nationwide real-life study
Respir Med
(2017) - et al.
Comorbidities in difficult-to-control asthma
J Allergy Clin Immunol Pract
(2018) - et al.
Efficacy of Nijmegen Questionnaire in recognition of the hyperventilation syndrome
J Psychosom Res
(1985) - et al.
Criteria to screen for chronic sinonasal disease
Chest
(2009) - et al.
A novel scoring system to distinguish vocal cord dysfunction from asthma
J Allergy Clin Immunol Pract
(2014) - et al.
Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
Respir Med
(2019)
Dedicated severe asthma services improve health-care use and quality of life
Chest
Systematic assessment for difficult and severe asthma improves outcomes and halves oral corticosteroid burden independent of monoclonal biologic use
J Allergy Clin Immunol Pract
The prevalence of severe refractory asthma
J Allergy Clin Immunol
The effects of telemedicine on asthma control and patients’ quality of life in adults: a systematic review and meta-analysis
J Allergy Clin Immunol Pract
Severe Asthma Global Evaluation (SAGE): an electronic platform for severe asthma
J Allergy Clin Immunol Pract
Persistent airflow obstruction in patients with asthma: characteristics of a distinct clinical phenotype
Respir Med
The utility of cardiopulmonary exercise testing in difficult asthma
Chest
Development of the asthma control test: a survey for assessing asthma control
J Allergy Clin Immunol
The St George's Respiratory Questionnaire
Respir Med
Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II)
Lancet
Inner City Asthma Study: relationships among sensitivity, allergen exposure, and asthma morbidity
J Allergy Clin Immunol
Effectiveness of indoor allergen reduction in asthma management: a systematic review
J Allergy Clin Immunol
Asthma: defining of the persistent adult phenotypes
Lancet
The global asthma report 2018
Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population
Thorax
The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry
Thorax
More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II
J Allergy Clin Immunol
Severe and difficult-to-treat asthma in adults
N Engl J Med
Management of severe asthma: a European Respiratory Society/American Thoracic Society Guideline
Eur Respir J
Precision medicine in airway diseases: moving to clinical practice
Eur Respir J
Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life
Respirology
Risk factors of frequent exacerbations in difficult-to-treat asthma
Eur Respir J
Severe asthma assessment checklist
Clinical review: checklists—translating evidence into practice
Crit Care
Reevaluation of diagnosis in adults with physician-diagnosed asthma
JAMA
Systematic assessment of difficult-to-treat asthma
Eur Respir J
The prevalence of nonadherence in difficult asthma
Am J Respir Crit Care Med
Nonadherence in the era of severe asthma biologics and thermoplasty
Eur Respir J
The hospital anxiety and depression scale
Acta Psychiatr Scand
Breathing pattern disorder in difficult asthma: characteristics and improvement in asthma control and quality of life after breathing re-training
Allergy
Novel assessment tool to detect breathing pattern disorder in patients with refractory asthma
Respirology
The ability of patient-symptom questionnaires to differentiate PVFMD from asthma
J Voice
Continuous laryngoscopy during provocation in the assessment of inducible laryngeal obstruction
Laryngoscope
High prevalence of laryngeal obstruction during exercise in severe asthma
Am J Respir Crit Care Med
Abnormal vocal cord function in difficult-to-treat asthma
Am J Respir Crit Care Med
Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care
Aliment Pharmacol Ther
A new method for measuring daytime sleepiness: the Epworth sleepiness scale
Sleep
Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome
Ann Intern Med
STOP questionnaire: a tool to screen patients for obstructive sleep apnea
Anesthesiology
Tracheobronchomalacia and excessive dynamic airway collapse: medical and surgical treatment
Semin Respir Crit Care Med
Cited by (31)
Biologic Super-Response and Clinical Remission in Severe Asthma
2023, Journal of Allergy and Clinical Immunology: In PracticeDifficult-to-Control Asthma Management in Adults
2022, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :The systematic assessment should also include an assessment for the presence of comorbidities and the impact of systemic corticosteroids on the patient. There is no universally agreed-upon way to perform a systematic assessment, but it is helpful for it to be based within a multidisciplinary team to ensure that a holistic approach is taken, which consistently answers the key questions to differentiate difficult-to-treat from severe asthma.13 The assessment should include review by a specialist in severe asthma and input as required from members of the multidisciplinary team, which can include nurse specialists, physiotherapists, pharmacists, allergists, rhinologists, gastroenterologists, and voice therapists.
Super-Responders to Severe Asthma Treatments: Defining a New Paradigm
2021, Journal of Allergy and Clinical Immunology: In PracticePrioritizing Treatable Traits in Airways Disease
2021, Journal of Allergy and Clinical Immunology: In PracticePragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma
2020, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Second, optimization of inhaler technique, medication adherence, and management of comorbidities, modifiable risk factors, and psychosocial circumstances is mandatory. For severe uncontrolled asthma, discussion at a severe asthma multidisciplinary team (MDT) should occur because there is growing evidence that this significantly reduces asthma-related hospital admissions and hospital days.9 Indeed, our Tayside severe asthma MDT has meetings on a weekly basis.
Advances in understanding and reducing the burden of severe asthma in children
2020, The Lancet Respiratory MedicineCitation Excerpt :For these children, a structured multidisciplinary assessment is necessary to diagnose asthma and to identify and address potentially modifiable factors that might be driving the persistence of symptoms. Depending on the referral criteria and resources available, many different practices have been described.12 The outcomes, however, are similar (figure 1 and panel 1).
M. Hew was funded by sabbatical leave from Alfred Health. All other authors report no funding for this manuscript.
Conflicts of interest: M. Hew has received grants-in-aid, speaker fees, and fees for serving on the advisory boards of GlaxoSmithKline, AstraZeneca, Novartis, Teva, Sanofi, and Seqirus, all paid to his institutional employer Alfred Health. A. Menzies-Gow reports attending advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim, Teva, and Sanofi; and receiving speaker fees from Novartis, AstraZeneca, Vectura, Boehringer Ingelheim, and Teva. He has participated in research with Astra Zeneca and attended international conferences with Teva. He has consultancy agreements with AstraZeneca, Vectura, and Sanofi. J. H. Hull reports speaking fees for lectures and advisory work from Novartis, Roche, Astra-Zeneca, and Teva. L. Fleming is an Asthma UK Senior Clinical Fellow supported by the Joan Bending, Evelyn Bending, Mervyn Stephens, and Olive Stephens Memorial Fellowship; and has received speaker fees and fees for attending advisory boards from Astra Zeneca, Boehringer-Ingelheim, GSK, Novartis, Respiri, Sanofi, and Teva, paid directly to her institution. C. Porsbjerg reports attending advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Teva, and Sanofi; and receiving speaker fees from Novartis, AstraZeneca, Sanofi, and Teva. She has participated in research with Astra Zeneca, Novartis, ALK, MSD, Teva, and Sanofi. A. T. Brinke reports research grants and institutional fees for lectures and advisory boards from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, and Teva. D. Allen has received speaker fees, paid contributions to advisory boards and support to attend conferences from AstraZeneca, Teva, and Napp. R. Gore reports personal fees from GlaxoSmithKline, UK; personal fees and nonfinancial support from Novartis UK; personal fees from Astra Zeneca, outside the submitted work. T. R. Tay declares no relevant conflicts of interest.